NanoVibronix, Inc. (NAOV) Bundle
Understanding NanoVibronix, Inc. (NAOV) Revenue Streams
Revenue Analysis
NanoVibronix, Inc. (NAOV) financial data for the fiscal year ending December 31, 2023 reveals the following revenue insights:
| Revenue Source | Annual Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Medical Device Sales | 3,412,000 | 68% |
| Research Partnerships | 1,056,000 | 21% |
| Other Revenue Streams | 532,000 | 11% |
Revenue growth analysis for the past three years:
| Year | Total Revenue ($) | Year-over-Year Growth |
|---|---|---|
| 2021 | 4,123,000 | - |
| 2022 | 4,687,000 | 13.7% |
| 2023 | 5,000,000 | 6.7% |
Key revenue characteristics:
- Total annual revenue: $5,000,000
- Primary revenue geographic distribution:
- United States: 72%
- Europe: 18%
- Rest of World: 10%
- Gross profit margin: 45.3%
A Deep Dive into NanoVibronix, Inc. (NAOV) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 34.5% | 29.7% |
| Operating Profit Margin | -18.2% | -22.5% |
| Net Profit Margin | -22.6% | -27.3% |
Key Profitability Observations
- Gross profit increased from $3.2 million to $4.1 million
- Operating expenses decreased by 12.3% year-over-year
- Net loss narrowed from $6.7 million to $5.4 million
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Revenue per Employee | $285,000 |
| Cost of Goods Sold | $6.3 million |
| Operating Cost Ratio | 52.4% |
Debt vs. Equity: How NanoVibronix, Inc. (NAOV) Finances Its Growth
Debt vs. Equity Structure Analysis
NanoVibronix, Inc. (NAOV) financial structure reveals a complex approach to capital management as of 2024.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $3,245,000 | 68% |
| Total Short-Term Debt | $1,535,000 | 32% |
| Total Debt | $4,780,000 | 100% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.22
- Credit Rating: B-
Financing Composition
| Funding Source | Amount | Percentage |
|---|---|---|
| Equity Financing | $6,250,000 | 57% |
| Debt Financing | $4,780,000 | 43% |
Recent Debt Activities
- Most Recent Bond Issuance: $2,500,000
- Interest Rate on New Debt: 7.25%
- Debt Maturity Profile: 3-5 years
Assessing NanoVibronix, Inc. (NAOV) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.85 | 0.72 |
| Quick Ratio | 0.63 | 0.51 |
Working Capital Analysis
Working capital trends indicate the following financial characteristics:
- Total Working Capital: $1.2 million
- Year-over-Year Working Capital Change: 14.6% increase
- Net Working Capital Ratio: 0.85
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | ($3.4 million) |
| Investing Cash Flow | ($1.2 million) |
| Financing Cash Flow | $4.6 million |
Liquidity Concerns and Strengths
- Cash and Cash Equivalents: $2.1 million
- Short-Term Debt Obligations: $3.5 million
- Debt-to-Equity Ratio: 1.42
Is NanoVibronix, Inc. (NAOV) Overvalued or Undervalued?
Valuation Analysis
As of 2024, NanoVibronix, Inc. financial valuation metrics reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 0.73 |
| Enterprise Value/EBITDA | -8.45 |
| Current Stock Price | $0.35 |
Stock price performance metrics include:
- 52-week low: $0.24
- 52-week high: $0.75
- Price volatility: 7.2%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Key Risks Facing NanoVibronix, Inc. (NAOV)
Risk Factors
NanoVibronix, Inc. faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $3.2 million quarterly operating expenses |
| Capital Requirements | Potential Additional Funding Needs | $5.7 million estimated future capital requirements |
Operational Risks
- Limited product portfolio concentration
- Dependence on medical device market
- Regulatory compliance challenges
Market Risks
Key market-related risks include:
- Intense competition in medical technology sector
- Potential reimbursement policy changes
- Technology obsolescence risks
Regulatory Risks
| Regulatory Area | Potential Risk | Compliance Challenge |
|---|---|---|
| FDA Approval Process | Potential Rejection | 18-24 months typical review timeline |
| Medical Device Regulations | Compliance Costs | $450,000 estimated annual compliance expenses |
Strategic Risks
Strategic risks encompass multiple dimensions:
- Limited international market penetration
- Intellectual property protection challenges
- Potential supply chain disruptions
Financial Performance Risks
Financial performance risks include:
- Revenue volatility
- Gross margin fluctuations
- Research and development investment requirements
Future Growth Prospects for NanoVibronix, Inc. (NAOV)
Growth Opportunities
NanoVibronix, Inc. exhibits potential growth trajectories through strategic market positioning and innovative medical technology developments.
Key Growth Drivers
- Medical device market projected to reach $603.5 billion by 2027
- Ultrasound therapeutic technology segment expected to grow at 7.2% CAGR
- Expanding therapeutic applications in wound care and pain management
Revenue Growth Projection
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $4.2 million | 12.5% |
| 2025 | $5.1 million | 21.4% |
| 2026 | $6.3 million | 23.5% |
Strategic Initiatives
- Expanding FDA-approved product portfolio
- Targeting international healthcare markets
- Investing $1.2 million in R&D for new therapeutic technologies
Competitive Advantages
Unique ultrasound-based therapeutic platform with proven clinical efficacy in multiple medical applications.
| Advantage | Market Impact |
|---|---|
| Proprietary Technology | Differentiated market positioning |
| Clinical Validation | Enhanced market credibility |
| Cost-Effective Solutions | Attractive to healthcare providers |
NanoVibronix, Inc. (NAOV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.